Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: Results of 4-year studies

Claus Roehrborn, Olavi Lukkarinen, Stephen Mark, Paul Siami, Joe Ramsdell, Norman Zinner

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

OBJECTIVE: To report additional analyses of efficacy over the initial 2 years and during a 2-year open-label extension of the three pivotal phase 3 studies in which dutasteride, a dual inhibitor of type 1 and 2 5α-reductase, was shown to be effective and well tolerated. PATIENTS AND METHODS: All patients in the placebo and active groups were eligible for entry into the 2-year open-label extension, with all receiving dutasteride 0.5 mg daily. Mean changes from baseline were calculated for the American Urologic Association Symptom Index (AUA-SI) score at each scheduled time in the double-blind and open-label phase. The additional analyses included a breakdown of the AUA-SI score, including stratifying patients by symptom severity, assessment by baseline age and prostate volume, and the evaluation of symptoms responders. RESULTS: There was a clinically meaningful improvement in AUA-SI in patients on dutasteride in the double-blind phase, but not in those on placebo. At 48 months, patients on dutasteride in both study phases had greater improvements in AUA-SI score and individual question scores than those on dutasteride in the open-label phase only. The proportion of patients with severe symptoms declined in both study groups, although these changes were more profound in those receiving dutasteride for the 4-year duration of the study. CONCLUSION: In men with symptomatic benign prostatic hyperplasia, long-term (4-year) treatment with the dual isozyme 5α-reductase inhibitor dutasteride resulted in sustained and continued improvements in symptoms and flow rate. For 4 vs 2 years, longer dutasteride therapy resulted in greater symptom improvement.

Original languageEnglish (US)
Pages (from-to)572-577
Number of pages6
JournalBJU International
Volume96
Issue number4
DOIs
StatePublished - Sep 2005

Fingerprint

Prostatic Hyperplasia
Oxidoreductases
Symptom Assessment
Placebos
Dutasteride
Isoenzymes
Prostate
Therapeutics

Keywords

  • BPH
  • Dutasteride
  • Long-term effects
  • Symptoms

ASJC Scopus subject areas

  • Urology

Cite this

Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride : Results of 4-year studies. / Roehrborn, Claus; Lukkarinen, Olavi; Mark, Stephen; Siami, Paul; Ramsdell, Joe; Zinner, Norman.

In: BJU International, Vol. 96, No. 4, 09.2005, p. 572-577.

Research output: Contribution to journalArticle

Roehrborn, Claus ; Lukkarinen, Olavi ; Mark, Stephen ; Siami, Paul ; Ramsdell, Joe ; Zinner, Norman. / Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride : Results of 4-year studies. In: BJU International. 2005 ; Vol. 96, No. 4. pp. 572-577.
@article{a7222e245ff04522980ba3d9f7a6dd6f,
title = "Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: Results of 4-year studies",
abstract = "OBJECTIVE: To report additional analyses of efficacy over the initial 2 years and during a 2-year open-label extension of the three pivotal phase 3 studies in which dutasteride, a dual inhibitor of type 1 and 2 5α-reductase, was shown to be effective and well tolerated. PATIENTS AND METHODS: All patients in the placebo and active groups were eligible for entry into the 2-year open-label extension, with all receiving dutasteride 0.5 mg daily. Mean changes from baseline were calculated for the American Urologic Association Symptom Index (AUA-SI) score at each scheduled time in the double-blind and open-label phase. The additional analyses included a breakdown of the AUA-SI score, including stratifying patients by symptom severity, assessment by baseline age and prostate volume, and the evaluation of symptoms responders. RESULTS: There was a clinically meaningful improvement in AUA-SI in patients on dutasteride in the double-blind phase, but not in those on placebo. At 48 months, patients on dutasteride in both study phases had greater improvements in AUA-SI score and individual question scores than those on dutasteride in the open-label phase only. The proportion of patients with severe symptoms declined in both study groups, although these changes were more profound in those receiving dutasteride for the 4-year duration of the study. CONCLUSION: In men with symptomatic benign prostatic hyperplasia, long-term (4-year) treatment with the dual isozyme 5α-reductase inhibitor dutasteride resulted in sustained and continued improvements in symptoms and flow rate. For 4 vs 2 years, longer dutasteride therapy resulted in greater symptom improvement.",
keywords = "BPH, Dutasteride, Long-term effects, Symptoms",
author = "Claus Roehrborn and Olavi Lukkarinen and Stephen Mark and Paul Siami and Joe Ramsdell and Norman Zinner",
year = "2005",
month = "9",
doi = "10.1111/j.1464-410X.2005.05686.x",
language = "English (US)",
volume = "96",
pages = "572--577",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride

T2 - Results of 4-year studies

AU - Roehrborn, Claus

AU - Lukkarinen, Olavi

AU - Mark, Stephen

AU - Siami, Paul

AU - Ramsdell, Joe

AU - Zinner, Norman

PY - 2005/9

Y1 - 2005/9

N2 - OBJECTIVE: To report additional analyses of efficacy over the initial 2 years and during a 2-year open-label extension of the three pivotal phase 3 studies in which dutasteride, a dual inhibitor of type 1 and 2 5α-reductase, was shown to be effective and well tolerated. PATIENTS AND METHODS: All patients in the placebo and active groups were eligible for entry into the 2-year open-label extension, with all receiving dutasteride 0.5 mg daily. Mean changes from baseline were calculated for the American Urologic Association Symptom Index (AUA-SI) score at each scheduled time in the double-blind and open-label phase. The additional analyses included a breakdown of the AUA-SI score, including stratifying patients by symptom severity, assessment by baseline age and prostate volume, and the evaluation of symptoms responders. RESULTS: There was a clinically meaningful improvement in AUA-SI in patients on dutasteride in the double-blind phase, but not in those on placebo. At 48 months, patients on dutasteride in both study phases had greater improvements in AUA-SI score and individual question scores than those on dutasteride in the open-label phase only. The proportion of patients with severe symptoms declined in both study groups, although these changes were more profound in those receiving dutasteride for the 4-year duration of the study. CONCLUSION: In men with symptomatic benign prostatic hyperplasia, long-term (4-year) treatment with the dual isozyme 5α-reductase inhibitor dutasteride resulted in sustained and continued improvements in symptoms and flow rate. For 4 vs 2 years, longer dutasteride therapy resulted in greater symptom improvement.

AB - OBJECTIVE: To report additional analyses of efficacy over the initial 2 years and during a 2-year open-label extension of the three pivotal phase 3 studies in which dutasteride, a dual inhibitor of type 1 and 2 5α-reductase, was shown to be effective and well tolerated. PATIENTS AND METHODS: All patients in the placebo and active groups were eligible for entry into the 2-year open-label extension, with all receiving dutasteride 0.5 mg daily. Mean changes from baseline were calculated for the American Urologic Association Symptom Index (AUA-SI) score at each scheduled time in the double-blind and open-label phase. The additional analyses included a breakdown of the AUA-SI score, including stratifying patients by symptom severity, assessment by baseline age and prostate volume, and the evaluation of symptoms responders. RESULTS: There was a clinically meaningful improvement in AUA-SI in patients on dutasteride in the double-blind phase, but not in those on placebo. At 48 months, patients on dutasteride in both study phases had greater improvements in AUA-SI score and individual question scores than those on dutasteride in the open-label phase only. The proportion of patients with severe symptoms declined in both study groups, although these changes were more profound in those receiving dutasteride for the 4-year duration of the study. CONCLUSION: In men with symptomatic benign prostatic hyperplasia, long-term (4-year) treatment with the dual isozyme 5α-reductase inhibitor dutasteride resulted in sustained and continued improvements in symptoms and flow rate. For 4 vs 2 years, longer dutasteride therapy resulted in greater symptom improvement.

KW - BPH

KW - Dutasteride

KW - Long-term effects

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=24044473719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044473719&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2005.05686.x

DO - 10.1111/j.1464-410X.2005.05686.x

M3 - Article

C2 - 16104912

AN - SCOPUS:24044473719

VL - 96

SP - 572

EP - 577

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 4

ER -